Ganeden recently developed a new immune-health solution called Staimune. Now, the company is announcing additional studies confirming the immune benefits of the novel ingredient which is gaining interest for formulation in a variety of food and beverage categories.
Staimune became available earlier this summer, and was developed using the inactivated cells of Ganeden’s patented and shelf-stable probiotic strain, GanedenBC30 (Bacillus coagulans GBI-30, 6086).
Numerous previous studies of the strain showed its impressive immune-supporting benefits, which prompted the company’s science team to delve further into the bacteria’s relationship to immunity. Research demonstrated that even when inactivated, the cells of GanedenBC30 continued to confer immune health benefits, leading to the introduction of Staimune.
In the latest study, previous lab studies were repeated to demonstrate that the immune effects of the cells were maintained, even when inactivated through a commercial production process. The results show that the inactivated bacterial cells had similar immune activation and anti-inflammatory effects as live cells.
Ganeden also recently completed a human trial, with initial findings demonstrating that Staimune supports a heathy immune system response to different stressors. Staimune offers functional immune health benefits when fortified into any food or beverage category, with the biggest opportunities in shelf-stable beverages and high-water-activity products, where there are formulation challenges for live probiotics.
The ingredient is FDA GRAS for usage in children and adults, and Ganeden has notified the FDA of self-affirmed GRAS for infant formula. It is also non-GMO, organic compliant and kosher, making it extremely accessible for use in a vast amount of applications, at cost-effective inclusion rates that don’t alter texture or flavor.